drugset
drugset / Trial / NCT04713930

A Study of JNJ-61393215 in Healthy Japanese Male Participants

NCT04713930 ↗

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose administrations of JNJ-61393215 in Japanese healthy adult male participants.

Timeline

Start
2021-01-29
Primary completion
2021-05-31
Completion
2021-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TEBITOREXANT Small molecule — Oral

Indications

No indication recorded.